Literature DB >> 25533782

Progressive brain metabolic changes under deep brain stimulation of subthalamic nucleus in parkinsonian rats.

Christophe Melon1, Carine Chassain, Guy Bielicki, Jean-Pierre Renou, Lydia Kerkerian-Le Goff, Pascal Salin, Franck Durif.   

Abstract

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an efficient neurosurgical treatment for advanced Parkinson's disease. Non-invasive metabolic neuroimaging during the course of DBS in animal models may contribute to our understanding of its action mechanisms. Here, DBS was adapted to in vivo proton magnetic resonance spectroscopy at 11.7 T in the rat to follow metabolic changes in main basal ganglia structures, the striatum, and the substantia nigra pars reticulata (SNr). Measurements were repeated OFF and ON acute and subchronic (7 days) STN-DBS in control and parkinsonian (6-hydroxydopamine lesion) conditions. Acute DBS reversed the increases in glutamate, glutamine, and GABA levels induced by the dopamine lesion in the striatum but not in the SNr. Subchronic DBS normalized GABA in both the striatum and SNr, and glutamate in the striatum. Taurine levels were markedly decreased under subchronic DBS in the striatum and SNr in both lesioned and unlesioned rats. Microdialysis in the striatum further showed that extracellular taurine was increased. These data reveal that STN-DBS has duration-dependent metabolic effects in the basal ganglia, consistent with development of adaptive mechanisms. In addition to counteracting defects induced by the dopamine lesion, prolonged DBS has proper effects independent of the pathological condition. Non-invasive metabolic neuroimaging might be useful to understand the physiological mechanisms of deep brain stimulation (DBS). Here, we demonstrate the feasibility of repeated high-field proton magnetic resonance spectroscopy of basal ganglia structures under subthalamic nucleus DBS in control and parkinsonian rats. Results show that DBS has both rapid and delayed effects either dependent or independent of disease state.
© 2014 International Society for Neurochemistry.

Entities:  

Keywords:  DBS; MRS; Parkinson's disease; microdialysis; striatum; substantia nigra

Mesh:

Year:  2015        PMID: 25533782     DOI: 10.1111/jnc.13015

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

Review 1.  Deep brain stimulation mechanisms: the control of network activity via neurochemistry modulation.

Authors:  Cameron C McIntyre; Ross W Anderson
Journal:  J Neurochem       Date:  2016-06-08       Impact factor: 5.372

2.  Chronic deep brain stimulation of the medial forebrain bundle reverses depressive-like behavior in a hemiparkinsonian rodent model.

Authors:  Luciano L Furlanetti; Volker A Coenen; Iñigo A Aranda; Máté D Döbrössy
Journal:  Exp Brain Res       Date:  2015-07-21       Impact factor: 1.972

3.  Deep Brain Stimulation of Hemiparkinsonian Rats with Unipolar and Bipolar Electrodes for up to 6 Weeks: Behavioral Testing of Freely Moving Animals.

Authors:  Kathrin Badstuebner; Ulrike Gimsa; Immo Weber; Armin Tuchscherer; Jan Gimsa
Journal:  Parkinsons Dis       Date:  2017-07-03

4.  Cellular, molecular, and clinical mechanisms of action of deep brain stimulation-a systematic review on established indications and outlook on future developments.

Authors:  Martin Jakobs; Anton Fomenko; Andres M Lozano; Karl L Kiening
Journal:  EMBO Mol Med       Date:  2019-04       Impact factor: 12.137

5.  Deep Brain Stimulation of the Subthalamic Nucleus Modulates Reward-Related Behavior: A Systematic Review.

Authors:  Yvan M Vachez; Meaghan C Creed
Journal:  Front Hum Neurosci       Date:  2020-11-20       Impact factor: 3.169

6.  Subthalamic Deep Brain Stimulation Affects Plasma Corticosterone Concentration and Peripheral Immunity Changes in Rat Model of Parkinson's Disease.

Authors:  Beata Grembecka; Wojciech Glac; Magdalena Listowska; Grażyna Jerzemowska; Karolina Plucińska; Irena Majkutewicz; Piotr Badtke; Danuta Wrona
Journal:  J Neuroimmune Pharmacol       Date:  2020-07-09       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.